KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $10.4 million.

  • Rigel Pharmaceuticals' Other Accumulated Expenses fell 10.27% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 10.27%. This contributed to the annual value of $10.4 million for FY2024, which is 94.90% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Other Accumulated Expenses stood at $10.4 million, which was up 94.90% from $5.3 million recorded in FY2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Other Accumulated Expenses peaked at $13.5 million during FY2021, and registered a low of $5.3 million during FY2023.
  • In the last 3 years, Rigel Pharmaceuticals' Other Accumulated Expenses had a median value of $6.5 million in 2022 and averaged $7.4 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Other Accumulated Expenses slumped by 51.98% in 2022 and then skyrocketed by 94.90% in 2024.
  • Rigel Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $11.0 million in 2020, then climbed by 22.63% to $13.5 million in 2021, then tumbled by 51.98% to $6.5 million in 2022, then decreased by 17.75% to $5.3 million in 2023, then spiked by 94.90% to $10.4 million in 2024.